[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"United Arab Emirates\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":682},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,47,70,114,144,167,190,211,233,257,289,322,347,369,389,412,434,478,507,526,549,573,604,636,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":7},"100579387","an-international-multicenter-study-on-transcatheter-device-closure-of-perimembranous-ventricular-septal-defects-100579387",false,"NCT06823635","An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects","PERI-CLOSE","Inclusion Criteria:\n\n1. Patients with perimembranous ventricular septal defects (PmVSD) diagnosed by 2D transthoracic echocardiography according to established classification systems, who provided informed consent and underwent transcatheter closure using any commercially available occluder devices (whether specifically designed for this indication or used off-label), with follow-up according to local hospital protocols.\n2. Defect size between 3 mm and \\\u003C20 mm on the left ventricular side, as measured by 2D echocardiography.\n3. Age ≥1 month and body weight ≥5 kg.\n4. Left-to-right ventricular shunt.\n\nExclusion Criteria:\n\n1. Patients or legal guardians refusing the use of personal data for research purposes.\n2. Failure to attend any follow-up visit post-discharge.","ALL","1 Month",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","The international multicenter registry aims to gather real-world data on patient outcomes and assess the procedural success and performance of various device occluders used in the transcatheter treatment of pediatric and adult patients with perimembranous ventricular septal defects (PmVSD).",[25],"Perimembranous Ventricular Septal Defect",[27,28,29,30,31,32,33,34],"Cardiovascular Abnormalities","Congenital Heart Disease","Device Closure","Heart Defects, Congenital","Heart Septal Defects","Heart Septal Defects, Ventricular","Transcatheter Interventions","Ventricular Septal Defects","RECRUITING","2026-08-24",{"date":38,"type":39},"2026-08-25","ACTUAL",{"date":41,"type":39},"2025-01-01",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"Fondation Hôpital Saint-Joseph","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100620627","long-term-outcomes-of-teplizumab-in-routine-clinical-care-100620627","NCT07360080","Long-Term Outcomes of Teplizumab in Routine Clinical Care","Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care","AL1GN","Inclusion Criteria -\n\n* Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.\n* Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.\n\n(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)\n\n• Participants (or their legal guardians, as applicable) who provide appropriate written or electronic informed consent\u002Fassent as applicable for the age of the participant and as per local regulations.\n\nExclusion Criteria -\n\n* Participants who had participated in a previous clinical trial for teplizumab.\n* Participants enrolled in a clinical trial within 6 months prior to study enrollment.\n\n(Note: Participants enrolled in other observational studies may be included.)\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":56,"type":21},1000,"This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.",[59],"Type 1 Diabetes","2026-08-21",{"date":38,"type":39},{"date":63,"type":39},"2026-03-19",{"date":65,"type":21},"2035-10-29",{"name":67,"class":68},"Sanofi","INDUSTRY",10,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":103,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347","NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","18 Years","65 Years",{"count":81,"type":21},130,"INTERVENTIONAL",[84],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102],"Diabetes Mellitus, Type 2","Diabetes Melletus","Glucose Metabolism Disorders","Metabolic Disorders","Nutritional and Metabolic Diseases","Endocrine System Diseases","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[104,95],"Ramadan","2026-08-20",{"date":60,"type":39},{"date":108,"type":39},"2026-07-15",{"date":110,"type":21},"2027-05",{"name":112,"class":68},"Eli Lilly and Company",40,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":82,"phases":124,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100559950","phase-2-a-phase-2-master-protocol-assessing-inebilizumab-and-blinatumomab-in-autoimmune-diseases-100559950","NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases","\\*Subprotocol A and B are no longer recruiting participants\\*\n\nInclusion Criteria:\n\n* Subprotocol A and B: Diagnosis of SLE according to 2019 European League Against Rheumatism and the American College of Rheumatology (ACR) classification criteria.\n* Subprotocol A and B: Participant must be positive for at least one of the following autoantibodies at screening (performed by central laboratory) or through documented history:\n\n  1. Antinuclear antibodies (ANA) ≥ 1:80\n  2. Anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies elevated to above normal range (ie, positive results)\n  3. AntiSmith antibodies elevated to above normal (ie, positive results).\n* Subprotocol A and B (Subgroup 1): Active, biopsy-proven, proliferative LN demonstrating class III or class IV with or without co-existing features of Class V LN (or pure Class V LN for Subprotocol B only) according to 2018 International Society of Nephrology\u002FRenal Pathology Society (ISN\u002FRPS) criteria. The local biopsy report will be used.\n* Subprotocol A and B: SLE Disease Activity Index 2K ≥ 6.\n* Subprotocol A and B (Subgroup 1): Inadequate response, loss of response or intolerance to at least 1 therapy (Subprotocol A) or 2 immunosuppressive therapies (Subprotocol B Subgroup 1) at the maximally tolerated doses as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (KDIGO, 2024). Inadequate response is defined as: UPCR ≥ 1.0 mg\u002Fmg.\n* Subprotocol B (Subgroup 2): Refractory SLE participants with inadequate response to multiple therapies (excluding hydroxychloroquine or corticosteroids) and have failed either a biologic agent or cyclophosphamide.\n* Subprotocol B (Part B Subgroup 2): British Isles Lupus Assessment Group (BILAG)-2004 level A disease in 1 organ system or BILAG-2004 level B disease in ≥ 2 organ systems\n* Subprotocol B (Part B Subgroup 2): Physician Global Assessment (PGA) ≥ 1\n* Subprotocol A and B: If receiving any of the following medications, participants must be on these doses prior to Day 1:\n\n  1. Prednisone dose ≤ 20 mg\u002Fday (or its equivalent in other corticosteroid forms) and at a stable dose for 5 days\n  2. Hydroxychloroquine dose ≤ 400 mg\u002Fday and at a stable dose for 4 weeks. Other equivalent antimalarials (chloroquine, quinacrine) are also accepted at a stable dose for 4 weeks.\n  3. MMF dose ≤ 3 g\u002Fday or MPA dose ≤ 2160 mg\u002Fday and at a stable dose for 2 weeks.\n  4. AZA dose ≤ 2 mg\u002Fkg\u002Fday and at a stable dose for 2 weeks.\n  5. Methotrexate \\> 25 mg\u002Fweek and at a stable dose for 2 weeks\n  6. Leflunomide \\> 20 mg\u002Fday and at a stable dose for 2 weeks\n  7. Dapsone \\> 300 mg\u002Fday and at a stable dose for 2 weeks.\n* Subprotocol C (Part A and Part B): Diagnosis of RA according to the 2010 ACR\u002FEuropean Alliance of Associations for Rheumatology (EULAR) classification criteria.\n* Subprotocol C (Part A and Part B): Moderate to severe disease activity as defined by DAS28-CRP \\> 3.2 with ≥ 3 swollen joints and ≥ 3 tender joints (based on 28 joint counts) at screening.\n* Subprotocol C (Part A and Part B): Refractory disease defined as:\n* Active disease despite having received treatment with:\n\n  1. at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD), AND\n  2. at least 2 biologic disease-modifying antirheumatic drugs (bDMARDs) of different mechanisms of action OR 1 bDMARD and at least 1 targeted synthetic disease-modifying antirheumatic drugs (tsDMARD).\n* Inadequate response or intolerance to csDMARDs, bDMARDs, and tsDMARDs should be defined as:\n\n  1. Participant having active disease despite a minimum of 12 weeks of treatment with a csDMARD, bDMARD, or tsDMARD.\n  2. Intolerance to treatment as defined by participant having experienced an adverse effect from treatment with a csDMARD, bDMARD, or tsDMARD.\n* Subprotocol C (Part B): High sensitivity C-Reactive Protein (hsCRP) level ≥ upper limit of normal per the central laboratory at screening.\n\nExclusion Criteria:\n\n* Subprotocol A, B and C: Receipt of a live and\u002For live attenuated vaccine within 4 weeks prior to first dose of trial drug, during the treatment period, or until B-cell repletion after the end of the treatment period. Administration of inactivated (killed) vaccines is acceptable.\n* Subprotocol A and B: Estimated glomerular filtration rate (eGFR) of \\\u003C 30 mL per minute per 1.73 m\\^2 of body surface area (calculated using the Modification of Diet in Renal Disease \\[MDRD\\] formula, with screening laboratory results for serum creatinine value).\n* Subprotocol A and B: Significant likely irreversible organ damage related to SLE (eg, end-stage renal disease \\[ESRD\\]).\n* Subprotocol A and B: Any acute, severe lupus related flare during screening that needs immediate treatment.\n* Subprotocol A and B: A previous kidney transplant or planned transplant within trial treatment period.\n* Subprotocol A and B: History of or current renal diseases (Parts A and B, Subgroup 1) that in the opinion of the investigator could interfere with the LN assessment and confound the disease activity assessment (eg, diabetic nephropathy).\n* Subprotocol A: Renal biopsy showing pure class V.\n* Subprotocol B: Active CNS Lupus within one year prior to screening.\n* Subprotocol B and C: History or presence of clinically relevant central nervous system (CNS) pathology or event such as seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or organic brain syndrome.\n* Subprotocol C: Prior history of current inflammatory joint disease other than RA including but not limited to SLE, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (eg, vasculitis, pulmonary fibrosis, or Felty's syndrome).\n* Subprotocol C: Functional Class IV as defined by the ACR classification of functional status in RA.\n* Subprotocol A, B and C: Receipt of the following medications or treatments at any time prior to Day 1:\n\n  1. B-cell directed CAR T-cell and T-cell engager therapies\n  2. Total lymphoid irradiation\n  3. Bone marrow transplant\n  4. T-cell vaccination therapy\n  5. Natalizumab","75 Years",{"count":123,"type":21},220,[125],"PHASE2","The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).",[128,129],"Systemic Lupus Erythematosus","Active Refractory Rheumatoid Arthritis",[131,132,133,134,135],"Systemic lupus erythematosus","Inebilizumab","Blinatumomab","Active refractory rheumatoid arthritis","Rheumatoid arthritis",{"date":60,"type":39},{"date":138,"type":39},"2025-07-16",{"date":140,"type":21},"2028-08-06",{"name":142,"class":68},"Amgen",58,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":82,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100548526","phase-3-pembrolizumab-with-or-without-maintenance-sacituzumab-tirumotecan-sac-tmt-mk-2870-in-metastatic-squamous-non-small-cell-lung-cancer-nsclc-mk-2870-023-100548526","NCT06422143","Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","Phase 3 Study of Pembrolizumab in Combination With Carboplatin\u002FTaxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \\[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\\]\n* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator\u002Fradiology\n* Has life expectancy ≥3 months\n* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation\n* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)\n* Has adequate organ function\n* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization\n* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit\n* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered\n* For Maintenance only (prior to randomization): has not experienced a pneumonitis\u002Finterstitial lung disease (ILD) event during the study-specified induction\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* History of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention\n* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and\u002For radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC\n* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC\n* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)\n* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications\n* Received prior treatment with a topoisomerase I inhibitor-containing ADC\n* Is currently receiving a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known central nervous system (CNS) metastases\u002Fcarcinomatous meningitis\n* Severe hypersensitivity (≥Grade 3) to study intervention and\u002For any of its excipients or to another biologic therapy\n* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \\[eg, thyroxine, insulin, or physiologic corticosteroid\\] is allowed)\n* Has a history of (noninfectious)pneumonitis\u002FILD that required steroids, has current pneumonitis\u002FILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening\n* Active infection requiring systemic therapy\n* History of allogeneic tissue\u002Fsolid organ transplant",{"count":152,"type":21},851,[84],"This is a phase 3 study of pembrolizumab in combination with carboplatin\u002Ftaxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).",[156,157],"Non-small Cell Lung Cancer","NSCLC","2026-08-19",{"date":105,"type":39},{"date":161,"type":39},"2024-06-10",{"date":163,"type":21},"2031-08-15",{"name":165,"class":68},"Merck Sharp & Dohme LLC",215,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100609545","a-real-world-study-to-evaluate-luspatercept-in-adults-with-transfusion-dependent-beta-thalassemia-in-the-middle-east-100609545","NCT07215975","A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East","REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study","Inclusion Criteria:\n\n* Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment\n* Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).\n* Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.\n* Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.\n* Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study\n\nExclusion Criteria:\n\n* Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC.\n* Participants who are currently receiving or are planned to receive treatment with any investigational drug\u002Fdevice\u002Fintervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation.\n* Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period.\n* Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.",{"count":175,"type":21},200,"The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East",[178],"β-thalassemia",[180],"Transfusion-dependent β-thalassemia","2026-08-18",{"date":158,"type":39},{"date":184,"type":39},"2026-06-26",{"date":186,"type":21},"2031-04-17",{"name":188,"class":68},"Bristol-Myers Squibb",13,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":82,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100606082","phase-2-brivekimig-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa-100606082","NCT07170917","Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa","A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa","BRIGHTEN","Inclusion Criteria:\n\n* Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline\n* Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which must be Hurley Stage II or Hurley Stage III.\n* Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.\n* Participants must be either biologic-naive or biologic-experienced.\n* Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline visit.\n* Participant must have a draining tunnel count of ≤20 at the Baseline visit.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS\n* History of recurrent or recent serious infection\n* Known history of significant immunosuppression\n* History of solid organ transplant or stem cell transplant\n* History of splenectomy\n* History of moderate to severe congestive heart failure.\n* History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease\n* Participants with a history of malignancy or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma of the skin that was excised and completely cured or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured\n* History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol\n* Active suicidality and therefore significant suicide risk, as judged by the Investigator\n* A history of an Adverse Event (AE) attributed to or related to anti-TNF therapy (examples include, but are not limited, to serum sickness or anaphylaxis) for an HS or non-HS indication that would contraindicate readministration of an anti-TNF class therapy\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study\n* History (within last 2 years prior to Baseline visit) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":199,"type":21},208,[125],"This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa.\n\nThe purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS.\n\nStudy details include:\n\nThe study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period.\n\nThe randomized treatment duration will be up to approximately 152 weeks",[203],"Hidradenitis Suppurativa",{"date":105,"type":39},{"date":206,"type":39},"2025-11-06",{"date":208,"type":21},"2029-11-23",{"name":67,"class":68},79,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":218,"sex":17,"minAge":219,"maxAge":78,"enrollmentInfo":220,"targetDuration":4,"studyType":82,"phases":222,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100595901","early-detection-of-type-1-diabetes-in-first-degree-relatives-of-type-1-diabetes-patients-detect-t1d-gulf-100595901","NCT07038473","Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)","Islet Autoantibody Early Detection in At-risk Children\u002FAdolescents to Predict Type 1 Diabetes: a Cohort Study in Gulf Countries","Inclusion Criteria:\n\n* Children and adolescents, age 1.5 years to 18 years\n* First degree relatives of T1D probands\n* Parent or legal guardian signing an informed consent\n\nExclusion Criteria:\n\n* Already developed clinical overt T1D\n* Known diabetes of any kind (type 1, type 2, Maturity Onset Diabetes of the Young - MODY)\n* Have a previous history of being treated with insulin\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",true,"18 Months",{"count":221,"type":21},3500,[223],"NA","The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D. This protocol has been developed to address the growing need for standardized T1D screening, monitoring, and data collection in alignment with international recommendations. The study's estimated duration is 13 months and will consist of two visits: Visit 1 (screening visit) and Visit 2 (confirmatory visit).",[59],{"date":158,"type":39},{"date":228,"type":39},"2025-12-17",{"date":230,"type":21},"2026-12-25",{"name":67,"class":68},7,{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":82,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100579098","phase-3-a-study-to-assess-the-efficacy-and-safety-of-induction-and-maintenance-therapy-with-afimkibart-ro7790121-in-participants-with-moderately-to-severely-active-crohns-disease-100579098","NCT06819878","A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease","SIBERITE-1","Inclusion Criteria:\n\n* Confirmed diagnosis of CD\n* Moderately to severely active CD\n* Bodyweight \\>= 40 kilogram (kg)\n* Demonstrated inadequate response, loss of response and\u002For intolerance to at least one protocol-specified conventional or advanced CD therapy\n* Males and females of childbearing potential must meet protocol criteria for contraception requirements\n\nExclusion Criteria:\n\n* Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis\n* Participant with a history of \\>= 3 bowel resections (\\> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)\n* Diagnosis of short gut or short bowel syndrome\n* Presence of an ileostomy, colostomy or ileoanal pouch\n* Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon\n* Presence of abdominal or perianal abscess\n* Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with \\>3 openings\n* Current diagnosis or suspicion of primary sclerosing cholangitis\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* Any past or current evidence of cancer of gastrointestinal tract, definite low-grade or high-grade colonic dysplasia\n* History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer\n* Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening\n* Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB\n* Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy","16 Years","80 Years",{"count":244,"type":21},600,[84],"This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).",[248],"Moderately to Severely Active Crohns Disease",{"date":105,"type":39},{"date":251,"type":39},"2025-03-17",{"date":253,"type":21},"2033-12-31",{"name":255,"class":68},"Hoffmann-La Roche",373,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100535509","observational-study-protocol-liver-r-100535509","NCT06252753","Observational Study Protocol: LIVER-R","An Observational Multi-Center Study to Evaluate Real-World Treatment Outcomes With or Without Durvalumab-Based Regimens in Hepatobiliary Cancers","LIVER-R","Inclusion Criteria General Inclusion Criteria\n\nAll patients must meet all of the following general criteria 1-4 along with all respective cohort specific criteria noted below:\n\n1. Age ≥18 years and a lawful adult in the country at the index date\n2. Confirmed presence of malignancy of primary hepatobiliary cancer by any method (e.g., radiological, histological, etc.)\n3. Decision to treat was made independently and prior to obtaining informed consent\n4. Informed consent was obtained as per country level regulations (includes waiver of consent for retrospective data collection if approved)\n\naBTC Specific Inclusion Criteria\n\nA patient will be eligible to be included in the aBTC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:\n\n1. Patient has unresectable aBTC\n2. Has received or is intending to receive a durvalumab-based regimen (may have been treated in an EAP)\n\nuHCC Specific Inclusion Criteria\n\nA patient will be eligible to be included in the uHCC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:\n\n1. Patient has unresectable uHCC\n2. Not eligible for LRT, as well as for those who progressed following LRT\n3. Has received or is intending to receive a durvalumab-based regimen (may have been treated in an EAP)\n\neeHCC Specific Inclusion Criteria\n\nA patient will be eligible to be included in the eeHCC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:\n\n1. HCC confirmed by radiological or histological diagnosis\n2. Child-Pugh A-B7\n3. Disease not amenable to curative treatment but amenable to LRT at index\n4. Patients with liver-confined HCC who initiated first non-curative intent LRT on or after 01 January 2024\n5. Patients eligible for LRT with palliative intent such as TACE\u002F TARE\u002Ftransarterial infusion chemotherapy (TAIC)\u002F hepatic arterial infusion chemotherapy (HAIC)\u002Ftransarterial embolization (TAE) given by itself or in combination with other systemic therapy (can include durvalumab) within 60 days of the LRT\n\nEMERALD Specific Inclusion Criteria\n\nA patient will be eligible to be included in the EMERALD cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:\n\n1. HCC confirmed by radiological or histological diagnosis\n2. Child-Pugh score of A-B7\n3. Liver-confined disease not amenable to curative treatment but amenable to LRT at index\n4. Receipt of a durvalumab-based regimen in combination with LRT administered within 28 days of each other (index is the first of the two treatments administered)\n\nExclusion Criteria\n\nGeneral Exclusion Criteria\n\nA patient will be excluded from participating in this study if they meet any of the following general criteria 1-2 or any cohort specific exclusion criteria:\n\n1. Currently\u002Fwas participating or plans to participate in any clinical trial for investigational treatment for hepatobiliary cancers on or after the diagnosis date until the index date\n2. Second primary malignancy prior to HCC or BTC diagnosis\n\naBTC Specific Exclusion Criteria\n\nA patient will be excluded from participating in the aBTC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:\n\n1. Received a liver transplant during the baseline period\n2. Received more than 1 cycle of Gemcitabine + Cisplatin for biliary tract cancer on or after diagnosis of unresectable, locally advanced or metastatic disease through the index date. Patients who received any systemic therapy while having early stage, resectable disease are eligible\n\nuHCC Specific Exclusion Criteria\n\nA patient will be excluded from participating in the uHCC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:\n\n1. Received a liver transplant during the baseline period\n2. Received other systemic therapies for hepatobiliary cancer indication on or after diagnosis date through the index date\n\neeHCC Specific Exclusion Criteria\n\nA patient will be excluded from participating in the eeHCC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:\n\n1. Eligible for curative therapy at the time of receiving LRT (ablation)\n2. Extrahepatic spread\n3. Portal vein tumor thrombosis (PVTT) of VP3\u002F4\n4. Receipt of systemic therapy prior to index LRT in the baseline period\n5. Liver transplant any time prior to index\n\nEMERALD Specific Exclusion Criteria\n\nA patient will be excluded from participating in the EMERALD cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:\n\n1. Eligible for curative therapy at the time of receiving LRT (ablation)\n2. Extrahepatic spread\n3. Portal vein tumor thrombosis (PVTT) of VP3\u002F4\n4. Receipt of systemic therapy prior to index LRT in the baseline period\n5. Liver transplant any time prior to index","130 Years",{"count":267,"type":21},4000,"Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multi-country, multi-center, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with or without a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of regimens (durvalumab-based or otherwise) in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, treatment provider characteristics, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, time to treatment discontinuation, recurrence-free survival, and time to treatment recurrence).",[270],"Hepatobiliary Cancers",[272,273,274,275,276,277,278],"Hepatobiliary cancer","Unresectable hepatocellular carcinoma (uHCC)","embolization eligible uHCC (eeHCC)","Advanced biliary tract cancer (aBTC)","Durvalumab","Observatory","Real-world","2026-08-12",{"date":281,"type":39},"2026-08-13",{"date":283,"type":39},"2023-12-19",{"date":285,"type":21},"2030-12-30",{"name":287,"class":68},"AstraZeneca",159,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":265,"enrollmentInfo":297,"targetDuration":4,"studyType":82,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100642669","a-phase-iiib-study-to-evaluate-camizestrant-plus-ribociclib-in-er-positive-her2-negative-advanced-breast-cancer-100642669","NCT07647328","A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients","SERAFA-1","Inclusion Criteria:\n\n1. Capable of giving signed informed consent.\n2. Female or male, must be ≥ 18 years or as per locally allowed age limit for screening.\n\n   Type of Participant and Disease Characteristics\n3. Histologically or cytologically documented diagnosis of ER+, HER2- BC based on local laboratory results and who are not amenable to resection or radiation therapy with curative intent.\n4. Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease.\n5. De novo Stage 4 disease, or recurrence from early CD stage breast cancer after having received standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation.\n6. ECOG performance status of 0 or 1.\n7. Adequate organ and marrow function. Sex and Contraceptive\u002FBarrier Requirements\n8. For those female or male patients who are not abstinent (in line with their preferred and usual lifestyle choice), and intend to be heterosexually active with a partner:\n\nFemale patients must be using highly effective contraceptive measures from the time of screening until 4 weeks after discontinuation of study treatment, and must have a negative serum pregnancy test before first dose of any study treatment if they are of childbearing potential; or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening:\n\n(a) Post-menopausal, defined as women with cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause: (i) Age ≥ 60 years (ii) Age \\\u003C 60 years with serum estradiol and FSH level within the laboratory's reference range for post-menopausal females (iii) Previous bilateral surgical oophorectomy (iv) Medically confirmed ovarian failure OR (b) Pre\u002Fperi-menopausal, ie, not meeting the criteria for being post-menopausal.\n\n(i) Pre-\u002Fperi-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \\[also known as leuprolide\\]). Patients must have concomitant treatment with LHRH agonists (goserelin or leuprorelin \\[leuprolide\\]) before or on the same day as the first dose of study treatment - and must be willing to continue on it for the duration of the study.\n\nNon sterilised male partners of a patient who is a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.\n\nMale participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening throughout the total duration of the programme and the drug washout period to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period.\n\nMale patients can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \\[also known as leuprolide\\]) unless the patients have clear orchiectomy medical history. Willingness to use 2 non-hormonal based methods of contraception throughout the study.\n\nExclusion Criteria:\n\n1. Participants who are not clinically indicated for endocrine therapy in combination with the CDK4\u002F6 inhibitor ribociclib.\n2. No evidence of advanced inoperable disease, or bone only disease with sclerotic\u002Fosteoblastic bone lesions only per standard of care imaging.\n3. Have advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term, and\u002For pulmonary lymphangitis.\n4. Persistent treatment-induced non-haematological toxicities (CTCAE Grade \\> 2).\n5. Known active infection including tuberculosis HBV and HCV.\n6. Known to have tested positive for HIV. Participants with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines.\n7. Any clinically important abnormalities in heart conduction patterns; participants with pacemakers or medically controlled atrial fibrillation are not excluded.\n8. Ongoing symptomatic hypotension.\n9. Pregnant or lactating women or patients not willing to use highly effective contraception as defined in the protocol.",{"count":298,"type":21},150,[84],"The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.",[302],"ER-Positive HER2-Negative Breast Cancer",[304,305,306,307,308,309,310,311,312],"Metastatic","Breast Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Next Generation Oral SERD","Antineoplastic Agents","Estrogen Receptor Antagonists","Camizestrant","2026-08-07",{"date":315,"type":39},"2026-08-10",{"date":317,"type":39},"2026-06-15",{"date":319,"type":21},"2029-02-28",{"name":287,"class":68},89,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":330,"minAge":78,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":346},"100640673","beyond-study-a-multicentre-prospective-observational-study-of-real-world-treatment-patterns-and-outcomes-of-trastuzumab-deruxtecan-in-patients-with-hr-positive-her2-low-or-ultra-low-metastatic-breast-cancer-previously-treated-with-endocrine-therapy-100640673","NCT07597993","BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","BEYOND","Inclusion Criteria:\n\n* -Female patients aged ≥18 years old at the time of T-DXd initiation\n* Patients with a confirmed histological or cytologically based diagnosis of HR-positive mBC.\n* Patients who were classified as HER2-low or HER2-ultralow mBC confirmed by the closest locally obtained HER2 test prior to or on the index date, and who meet the following definitions:\n* HER2-low status defined as IHC scores 1+ and 2+ without ISH gene amplification based on the pathology report.\n* HER2-ultralow status defined as IHC 0 with membrane staining based on the pathology report.\n* Patient who received at least one prior line of ET (± targeted therapy) in the metastatic setting.\n* Patients who are chemotherapy-naïve in the metastatic setting.\n* Patients who initiated T-DXd up to 30 days before the signature of the ICF. The decision to initiate T-DXd must be made independently by treating physicians as part of routine clinical practice.\n* Patients are willing to sign the written ICF, indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n* -Patients with a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.\n* Patients who received prior chemotherapy in the metastatic setting.\n* Patients with Eastern Cooperative Oncology Group (ECOG) status ≥2 or missing ECOG status at the time of initiation of T-DXd (index date).\n* Patients with a history of participation in another clinical trial in the metastatic setting.\n* Female patient with current or planned pregnancy, or breastfeeding.","FEMALE",{"count":332,"type":21},109,"BEYOND study is designed to generate the first real-world data from GCC countries on the patient characteristics, treatment patterns, survival outcomes, and safety of T-DXd in patients with HRpositive,HER2-low or HER2-ultralow mBC previously treated with ET. The evidence generated will help to optimise treatment strategies, inform clinical guidelines, and ultimately improve outcomes for patients with mBC across the region.",[335],"Breast Cancer",[337,338],"breast cancer","Trastuzumab Deruxtecan","2026-08-06",{"date":315,"type":39},{"date":342,"type":39},"2026-07-12",{"date":344,"type":21},"2029-03-31",{"name":287,"class":68},9,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":82,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":368},"100587321","a-study-of-izalontamab-brengitecan-versus-chemotherapy-in-participants-with-previously-untreated-locally-advanced-recurrent-inoperable-or-metastatic-triple-negative-breast-cancer-ineligible-for-anti-pdl1-drugs-izabright-breast01-100587321","NCT06926868","A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2\u002F3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1\u002FPD-L1 Treatment","Inclusion Criteria\n\n* Histologically or cytologically confirmed and documented locally-advanced, recurrent inoperable, or metastatic triple-negative breast cancer (TNBC) (ER \\\u003C 1%, PgR \\\u003C 1%, HER2 IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) or ER-low, HER2-negative BC (ER and \u002F or PgR 1% to 10%, HER2 IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) per American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO\u002FCAP) criteria, based on the most recently analyzed biopsy or other pathology specimen.\n* Patients with recurrent disease must have experienced disease relapse at least 6 months after finishing their last therapy with curative intent.\n* Participants with TNBC must be considered ineligible for 1L chemotherapy combination treatment with an anti-PD-1 (eg, pembrolizumab) or an anti-PD-L1 (eg, atezolizumab) due to any one of the following criteria:\n\n  i) Investigator-determined ineligibility based on PD-L1 negative disease determined and documented prior to trial screening as part of standard of care (SoC); ii) Has experienced disease relapse between 6 to 12 months after the completion of (neo)adjuvant therapy with an anti-PD(L)1; iii) Has a severe auto-immune disease or other contraindication, in the opinion of the investigator, for the use of an anti-PD(L)1 drug: iv) Any auto-immune disease that requires current immunosuppression (eg, methotrexate, cyclophosphamide, prednisone \\> 10 mg\u002Fday).\n\n  v) Prior auto-immune AE to peri-adjuvant ICI that required immunosuppression. vi) Current Graves' disease with ophthalmopathy or in need of radioiodine or in use of antithyroid medication.\n\nvii) Current or prior auto-immune diseases per below: A. Moderate to severe rheumatoid arthritis. B. Auto-immune hepatitis or cholangitis. C. Myasthenia gravis. D. Moderate-to-severe or poorly controlled inflammatory bowel disease. E. Multiple sclerosis. F. Lupus with kidney involvement or moderate to severe lupus. G. Auto-immune myocarditis. Note: if participant meets Inclusion Criteria 5b or 5c, unknown PDL1 results per local SOC are acceptable in these specific cases.\n\n* Patients with ER-low, HER2-negative BC must be ineligible, in the opinion of the Investigator, for endocrine therapy-based treatments.\n* No previous systemic therapy in the locally advanced, recurrent inoperable or metastatic setting (ie incurable setting).\n* Measurable disease by CT or MRI as per RECIST v1.1.\n\nExclusion Criteria\n\n* Participants with a known germline breast cancer gene (BRCA) 1 or 2 mutation whose best 1L treatment option, in the opinion of the investigator, is a poli-ADP-ribose-polymerase inhibitors (PARPi).\n* Untreated symptomatic central nervous system (CNS) metastases. Participants are eligible if CNS metastases have been treated, and participants' neurological signs and symptoms have returned to baseline. In addition, participants must have been either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization. Imaging performed within 28 days of randomization must document radiographic stability of CNS lesions and be performed after completion of any CNS directed therapy.\n* Leptomeningeal metastases.\n* Participants with history of severe heart disease including, but not limited to, any of the following:\n\n  i) History of clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification II to IV, pericarditis, or significant pericardial effusion).\n\nii) Myocardial infarction, uncontrolled angina, or stroke\u002Ftransient ischemic attack within the past 6 months.\n\niii) QTc (by Fridericia's formula) prolongation ≥ 450 msec for males and ≥ 470 msec for females, except for right bundle branch block.\n\niv) Known LVEF \\\u003C 50%.\n\n* Prior therapy with iza-bren or any other ADC targeting EGFR and\u002For HER3 or containing a topoisomerase 1 inhibitor payload.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":244,"type":21},[125,84],"The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.",[305],[359,360,361],"triple-negative breast cancer","antibody-drug conjugate","ER-low\u002FHER2-negative breast cancer",{"date":315,"type":39},{"date":364,"type":39},"2025-09-11",{"date":366,"type":21},"2030-05-15",{"name":188,"class":68},295,{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":377,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":210},"100615299","this-study-is-a-non-interventional-disease-registry-of-adolescent-and-adult-patients-with-atopic-dermatitis-who-initiate-or-switch-any-systemic-treatment-100615299","NCT07290803","This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments","ARMADA-AD","Inclusion Criteria:\n\n* Patients aged more than or equal to (≥) 12 years at the time of consent.\n* Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20.\n* Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)\n* Signed informed consent for registry participation by the patient or parent\u002Flegal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.\n\nExclusion Criteria:\n\n* Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care.\n* Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","12 Years",{"count":56,"type":21},"The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.\n\nThe study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.",[381],"Atopic Dermatitis","2026-08-05",{"date":339,"type":39},{"date":385,"type":39},"2025-11-17",{"date":387,"type":21},"2034-01-30",{"name":67,"class":68},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":396,"maxAge":121,"enrollmentInfo":397,"targetDuration":4,"studyType":82,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":411},"100623633","phase-2-study-to-evaluate-the-effect-of-ht-4253-for-the-prevention-of-alzheimers-disease-in-apoe4-carriers-100623633","NCT07399171","Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","Inclusion Criteria:\n\n1. Participant must be 50-75 years of age, without previous AD diagnosis at the time of signing the informed consent.\n2. Capable of giving signed informed consent.\n3. Body mass index (BMI) between 18 and 32 kg\u002Fm2.\n4. A positive amyloid probability score from PrecivityAD2™ test (≥ 47.5).\n5. APOE4 carrier: homozygous (APOE4\u002FAPOE4) or heterozygous (APOE3\u002FAPOE4), confirmed using the Precivity-ApoE™ test.\n6. Must be ambulatory.\n7. Must be in good health, as determined by the PI, without clinically significant medical history.\n8. Normal physical examination, 12-lead ECG, and vital signs, as determined by the PI.\n9. Females must meet one of the following:\n\n   * Postmenopausal\n   * Surgically sterile\n10. Male participants who are sexually active with a woman of childbearing potential must agree to use a double contraception during the study and for 30 days after the last dose of HT-4253.\n11. Female participants must have a negative serum pregnancy test (β-human chorionic gonadotropin \\[β-hCG\\]) at screening.\n12. Able to comply with the study procedures in the view of the PI.\n\nExclusion Criteria:\n\n1. Any medical or neurological condition that in the opinion of the PI may be supportive of dementia.\n2. A history of subjective memory decline with gradual onset and slow progression over the 6 months prior to Screening.\n3. Previous or current diagnosis of AD or mild cognitive decline: MoCA \\\u003C 26.\n4. Any clinically significant CNS, cardiac, pulmonary, renal, gastrointestinal, endocrinological, respiratory, or metabolic conditions (or history), or other pathological or physiological conditions, that might interfere with the study results in the PI's opinion.\n5. Any condition which, in the PI's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study.\n6. History of clinically significant unstable psychiatric illness at the PI's discretion (e.g., uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder) Note: Well-controlled and stable major depressive disorder or anxiety is permitted.\n7. Prior treatment with an investigational LRRK2 inhibitor or any investigational AD therapy within the 6 months prior to Screening.\n8. Concomitant use of prescription medications primarily indicated for psychiatric disorders or neurodegenerative disease (e.g., antipsychotics, mood stabilizers, investigational agents) within 30 days prior to first dose of study drug (Study Day 1).\n9. Transient ischemic attack or stroke or any unexplained loss of consciousness (e.g., fainting without a diagnosis) within 1 year prior to Screening.\n10. Known cerebral or systemic vasculopathy.\n11. History of seizure or convulsion within 3 years prior to Screening or progressive neurologic disease (Parkinson's with dementia, epilepsy with breakthrough seizures, normal pressure hydrocephalus, multiple sclerosis with recent relapse).\n12. Have donated blood or had loss of blood of more than a single unit of blood within 8 weeks before Screening or intend to donate blood during the course of the study.\n13. Poorly controlled diabetes mellitus, as defined by having dosage adjustment of diabetic medication within 3 months prior to first dose of study drug (Study Day 1).\n14. History of unstable angina, myocardial infarction, and\u002For chronic heart failure.\n15. Chronic, uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 95 mmHg).\n16. Vaccinations within 10 days prior to Screening.\n17. Use of any medications, including prescription, over the counter (OTC) medications, vitamins, herbal preparations, and supplements, that, in the opinion of the PI, may put the participant at higher risk for AEs, or impair the participant's ability to complete study procedures.\n18. Use of other investigational drugs at the time of Screening or within 30 days or 5 half-lives prior to signing of the ICF, whichever is longer, or longer if required by local regulations.\n19. History of heavy smoking (i.e., more than 10 cigarettes a day or the tobacco\u002Fnicotine equivalent) within 3 months of Screening or refuse to abstain from tobacco or nicotine-containing products throughout the duration of the study.\n20. History of, or current substance use disorder, including heavy alcohol use.\n21. Pregnant or breastfeeding.\n22. Presence of any laboratory abnormalities at Screening.\n23. Prolonged QT interval exclusions for QTcF \\>450 ms for males and \\>470 ms for females Note: Entry of any participant with an abnormal ECG must be approved and documented by signature of the PI or a medically qualified sub-investigator.\n24. Impaired renal function with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2.","50 Years",{"count":398,"type":21},112,[125],"Primary Objectives:\n\nTo demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score.\n\nSecondary Objectives:\n\n* To assess the effects of HT-4253 on tau related blood biomarker progression over the study period.\n* To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period.\n* To assess the safety and tolerability of HT-4253 in the UAE population.",[402],"Alzheimers Disease","2026-08-03",{"date":382,"type":39},{"date":406,"type":39},"2026-05-12",{"date":408,"type":21},"2028-07",{"name":410,"class":68},"Halia Therapeutics, Inc.",3,{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":433},"100550445","a-study-observing-everyday-effectiveness-and-safety-of-the-drug-elafibranor-in-participants-with-primary-biliary-cholangitis-who-are-receiving-ongoing-treatment-100550445","NCT06447168","A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment","Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg\u002FDay in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.","ELFINITY","Inclusion Criteria:\n\n* Participant has provided written informed consent and agrees to comply with the study protocol.\n* Participant with PBC diagnosis.\n* Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor.\n* If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.\n\nExclusion Criteria:\n\n* Participant is currently participating or, plans to participate in an investigational drug study or medical device study containing active substance.\n* Participant with known hypersensitivity to the product or to any of its excipients.\n* Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.",{"count":421,"type":21},424,"This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting.\n\nPBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged.\n\nThe liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms including pruritus (itching) and fatigue. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.\n\nIn this study the main aim is to observe the effectiveness, safety and tolerability of elafibranor in participants with PBC who are receiving treatment in real world setting. The total study duration for each participants will be 60 months (approximately 5 years).",[424],"Primary Biliary Cholangitis","2026-07-31",{"date":403,"type":39},{"date":428,"type":39},"2024-10-14",{"date":430,"type":21},"2032-07-15",{"name":432,"class":68},"Ipsen",74,{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":441,"maxAge":396,"enrollmentInfo":442,"targetDuration":4,"studyType":82,"phases":443,"briefSummary":444,"conditions":445,"keywords":451,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":475,"locationsCount":477},"100650060","precision-lifestyle-medicine-program-for-ifhas-participants-100650060","NCT07742917","Precision Lifestyle Medicine Program for IFHAS Participants","Application of a Precision Lifestyle Medicine Clinical Program for a Sample of IFHAS Screening Cohort","Inclusion Criteria:\n\n* Emiratis residing in Abu Dhabi emirate\n* Aged 25-50 years\n* BMI 30-35 kg\u002Fm²\n* Thiqa cardholder\n* Previous participation in IFHAS screening\n* Able to provide informed consent\n* Participant in the Emirati Genome Programme\n* No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment.\n\nExclusion Criteria:\n\n* Aged under 25 years or over 50 years of age\n* BMI range under 30 kg\u002Fm2 and over 35 kg\u002Fm2\n* Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)\n* Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)\n* Transplant surgery within 12 months\n* Pregnancy\n* Surgery within 3 months prior to recruitment\n* Physical limitations preventing exercise participation\n* Current enrolment in other lifestyle intervention programs\n* Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation\n* Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.","25 Years",{"count":298,"type":21},[223],"The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg\u002Fm²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:\n\n* Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention?\n* Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population?\n\nResearchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health.\n\nParticipants will:\n\n* Take part in an 18-week personalized lifestyle medicine program tailored to their health profile.\n* Attend study visits and complete health assessments over a total study period of 24 weeks.\n* Undergo cardiometabolic biomarker assessments before and after the intervention.\n* Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic.\n* Provide biological samples to support the establishment of a biomarker repository for future research.",[446,447,448,449,450],"Obese Adults","BMI\u002FBody Composition","Cardiometabolic Risk","Cardiovascular Disease Risk","Type 2 Diabetes Risk",[452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469],"cardiovascular","obesity","BMI","UAE","Emirati","IFHAS","Personalized","Precision Lifestyle Medicine","Emirati Population","Cardiovascular Disease Prevention","Type 2 Diabetes Prevention","Biological Age","Continuous Glucose Monitoring (CGM)","Oura ring","Gut Microbiome","Preventive Medicine","Personalized Nutrition","Risk Stratification","2026-07-29",{"date":403,"type":39},{"date":403,"type":21},{"date":474,"type":21},"2027-12-13",{"name":476,"class":46},"Institute for Healthier Living Abu Dhabi",1,{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":218,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":82,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":498,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":477},"100649736","neural-cognitive-and-biomechanical-determinants-of-falls-in-older-adults-100649736","NCT07739056","Neural, Cognitive, and Biomechanical Determinants of Falls in Older Adults","Neural, Cognitive, and Biomechanical Determinants of Falls in Older Adults: A Two-Phase Multimodal Investigation With a Phenotype-Guided Rehabilitation Trial","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Age ≥ 65 years\n  * Community-dwelling\n  * Ability to ambulate independently (with or without assistive device)\n  * Ability to understand instructions and provide informed consent\n\nParticipants will be stratified into fall-risk categories based on established criteria:\n\n* High fall risk: history of ≥1 fall in the previous 12 months and\u002For impaired functional performance (e.g., TUG \\> 13.5 s or BBS ≤49)\n* Low\u002Fno fall risk: no falls and preserved functional mobility These criteria are consistent with previously published fall-prevention trials.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have:\n\n  * Neurological conditions affecting gait or balance (e.g., stroke, Parkinson's disease)\n  * Severe musculoskeletal disorders limiting mobility\n  * Severe cognitive impairment (e.g., inability to follow instructions or MoCA \\\u003C 18)\n  * Uncontrolled cardiovascular or metabolic conditions\n  * Current participation in structured rehabilitation programs\n  * Contraindications to EEG, EMG, or fNIRS measurements",{"count":486,"type":21},80,[223],"The goal of this clinical trial with an embedded observational phase is to evaluate whether a phenotype-guided, personalized rehabilitation program can improve fall risk and underlying neural control mechanisms in older adults aged ≥65 years, including both high and low fall-risk individuals.\n\nThe main questions it aims to answer are:\n\nDo older adults at high fall risk exhibit altered neural, neurocognitive, and biomechanical profiles compared with low\u002Fno fall-risk individuals? Does personalized rehabilitation guided by neurophysiological and neurocognitive profiles result in greater reductions in fall risk and improvements in motor control compared with conventional rehabilitation?\n\nResearchers will compare personalized phenotype-guided rehabilitation to conventional evidence-based fall-prevention exercise to determine whether targeted, mechanism-based intervention leads to superior clinical and mechanistic outcomes.\n\nParticipants will:\n\nUndergo a comprehensive multimodal assessment including neurophysiological (EEG, EMG), neurocognitive (fNIRS, dual-task testing), and biomechanical (gait and balance) measures Be classified into fall-risk and neurophysiological control profiles based on assessment results (Phase 2 - high fall-risk participants only) be randomly assigned to either personalized rehabilitation or conventional rehabilitation Attend supervised exercise sessions 2-3 times per week for 8-12 weeks Complete gait, balance, and cognitive-motor assessments before and after the intervention Record falls prospectively using monthly fall diaries and follow-up monitoring over 3-6 months",[490],"Accidental Falls\u002FPrevention & Control",[492,493,494,495,496,497],"Fall risk","Older adults","Balance","Neural control","Cognitive-motor integration","Phenotype-guided therapy","NOT_YET_RECRUITING","2026-07-27",{"date":425,"type":39},{"date":502,"type":21},"2026-12-31",{"date":504,"type":21},"2028-12-31",{"name":506,"class":46},"University of Sharjah",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":377,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":232},"100628893","the-impact-of-dupilumab-treatment-on-anxiety-and-depression-symptoms-in-patients-with-moderate-to-severe-atopic-dermatitis-100628893","NCT07467564","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries","DERMIND-AD","Inclusion Criteria:\n\n* Participants who have moderate to severe AD with signs and symptoms of anxiety and\u002For depression.\n* Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation\n* Participants and\u002For their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating, or planning\u002Fintending to be pregnant in the next 6 months.\n* Participants who are participating in another trial.\n* Participants with active chronic or acute infection requiring systemic treatment.\n* Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection.\n* Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses.\n* Participants on antidepressants\u002Fanti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants\u002Fanti-anxiety. In addition, those who will use antidepressants\u002Fanti-anxiety medications throughout the study will be excluded from the analysis.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":516,"type":21},184,"This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.",[381],{"date":520,"type":39},"2026-07-28",{"date":522,"type":39},"2026-02-24",{"date":524,"type":21},"2027-05-24",{"name":67,"class":68},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":533,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":82,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":548},"100498175","phase-2-patiromer-for-treatment-of-hyperkalaemia-in-children-under-12-years-of-age-100498175","NCT05766839","Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age","A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)","Inclusion Criteria:\n\n* Paediatric participants (\\\u003C12 years of age) with hyperkalaemia at screening.\n* Participant's age should not reach 12 years during the 28 days of the pharmacodynamic\u002Fdose-ranging period.\n* Participant is able to receive regular external feeding and medication, including via tubes, i.e., percutaneous endoscopic gastrostomy (PEG) or entero-gastric feeding tube.\n* At screening\u002Fbaseline, the results from 2 separate and consecutive potassium assessments using the same measurement method (whole blood, plasma, or serum) need to be above the age-appropriate upper limit of normal (ULN).\n* If taking any renin-angiotensin aldosterone system inhibitors (RAASi), beta blockers, fludrocortisone, or diuretic medications, must be on a stable dose for at least 14 days prior to screening.\n* Parent(s) or legally authorised representative(s) or another appropriate person delegated by the legally authorised representatives must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day; accurately and reliably dispense investigational product as directed.\n* Females of childbearing potential must be non-lactating, must have a negative pregnancy test at screening, and must have used an effective, acceptable form of contraception (e.g., abstinence) for at least 1 month before patiromer administration. Females of childbearing potential must agree to continue using contraception throughout the study and for 1 month after the last dose of patiromer.\n* If undergoing peritoneal dialysis, participants must be on a stable treatment plan for a minimum of 4 weeks prior to screening, or at least 8 weeks prior to screening if newly initiated on peritoneal dialysis.\n\nExclusion Criteria:\n\n* Preterm birth infants with \\\u003C37 weeks of gestation cannot be included in Cohort 3.\n* Participants who due to their general condition, e.g., anaemia or low body weight, are not suitable to have blood volume withdrawn.\n* Any of the following renal conditions: maintenance haemodialysis, renal artery stenosis, and acute kidney injury (defined by 2012 Kidney Disease Improving Global Outcomes) or a history of acute renal insufficiency in the past 3 months. Note: Chronic kidney disease (CKD) is not excluded.\n* A history of or current diagnosis of a severe gastrointestinal (GI) diagnosis or surgery that could affect GI transit of the drug (delayed gastric emptying), such as a severe swallowing disorder, severe gastroesophageal reflux, uncorrected pyloric stenosis, intussusception, any other intestinal obstruction (e.g., Hirschsprung disease, chronic intestinal pseudo-obstruction, clinically significant postsurgical abdominal adhesions) or any gut-shortening surgical procedure prior to screening. Pre-gastric above-mentioned pathologies may be disregarded in case of existence of a PEG or entero-gastric feeding tube, as the PEG or entero-gastric feeding tube will serve for nutrition and investigational product administration.\n* Active cancer, currently on cancer treatment, or history of cancer in the past 2 years (except for non-melanoma skin cancer).\n* Scheduled for kidney transplant procedure during the first 28 days after Day 1.\n* History of sudden infant death in a sibling (only for participants \\\u003C2 years of age at screening).\n* Use of the following medications if doses have not been stable for at least 14 days prior to screening or if doses are anticipated to change during the 4-week pharmacodynamic\u002F\n* Dose-ranging period: digoxin, bronchodilators, theophylline, heparins (including low molecular heparins), tacrolimus, mycophenolate mofetil, cyclosporine, trimethoprim, or cotrimoxazole.\n* Use of any investigational product for an unapproved indication within 30 days prior to screening or within 5 half-lives, whichever is longer.\n* Known hypersensitivity to patiromer or its components.\n* If the child is being breastfed:\n\n  1. There is suspicion of current alcohol or substance misuse\u002Fabuse in breastfeeding mother.\n  2. The breastfeeding mother is taking potassium supplements\n* Other protocol defined Inclusion\u002FExclusion criteria may apply.","0 Years","11 Years",{"count":536,"type":21},32,[125],"A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.",[540],"Hyperkalemia",{"date":520,"type":39},{"date":543,"type":39},"2025-04-06",{"date":545,"type":21},"2030-12-01",{"name":547,"class":68},"Vifor Pharma, Inc.",37,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":82,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":572},"100583779","phase-3-study-of-plozasiran-in-adults-with-severe-hypertriglyceridemia-at-risk-of-acute-pancreatitis-100583779","NCT06880770","Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis","Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)","SHASTA-5","Inclusion Criteria:\n\n* Males, or nonpregnant (who do not plan to become pregnant) nonlactating females\n* Established diagnosis of SHTG and prior documented evidence of fasting TG levels of ≥ 880 mg\u002FdL (≥ 10 mmol\u002FL)\n* Documented evidence of at least 1 prior AP event not attributed to other etiologies occurring within the last 60 months prior to Screening.\n* Fasting low-density lipoprotein cholesterol (LDL-C) ≤ 130 mg\u002FdL (≤ 3.37 mmol\u002FL) at Screening\n* Screening hemoglobin A1c (HbA1c) ≤ 9.5%\n* Willing to follow diet counseling and maintain a stable low-fat diet\n* Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)\n\nExclusion Criteria:\n\n* Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and\u002For triglycerides within 365 days before Day 1, except inclisiran.\n* Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer.\n* AP ≤ 4 weeks prior to Randomization\u002FDay 1\n* Body mass index (BMI) \\> 45 kg\u002Fm\\^2\n* Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)\n* Planned coronary intervention (e.g. stent placement or heart bypass) during the study\n* History of arterial revascularization within 16 weeks of Screening\n* History of acute coronary syndrome event within 24 weeks of Screening\n* Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening\n* Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study\n* History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening\n* New York Heart Association Class III-IV heart failure or last known ejection fraction of \\\u003C 30%\n* Current diagnosis of nephrotic syndrome\n* Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \\\u003C 20 mL\u002Fmin\u002F1.73 m\\^2\n* Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5× Upper Limit of Normal (ULN) at Screening\n\nNote: Additional Inclusion\u002FExclusion Criteria may apply per protocol",{"count":558,"type":21},288,[84],"This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.",[562],"Severe Hypertriglyceridemia","2026-07-22",{"date":565,"type":39},"2026-07-23",{"date":567,"type":39},"2025-04-24",{"date":569,"type":21},"2029-06",{"name":571,"class":68},"Arrowhead Pharmaceuticals",102,{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":330,"minAge":78,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":82,"phases":583,"briefSummary":584,"conditions":585,"keywords":588,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":477},"100648763","phase-2-efficacy-of-recombinant-human-g-csf-in-women-with-unexplained-recurrent-miscarriage-100648763","NCT07724405","Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage","A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer","GEM","Inclusion:\n\n1. Women aged 18-44 years\n2. ≥2 unexplained pregnancy losses\n3. Undergoing IVF with PGT-A tested embryos\n4. BMI 19-35 kg\u002Fm² 6.\n\nExclusion:\n\n1. Parental karyotype abnormalities\n2. Correctable uterine abnormalities\n3. Systemic autoimmune disease \u002F thrombophilia\n4. Uncontrolled systemic illness (e.g. diabetes, infection)\n5. Previous G-CSF therapy\n6. Hypersensitivity to rhG-CSF or E. coli proteins\n7. HIV, malignancy within 5 years, or severe cardiovascular\u002Frespiratory history","44 Years",{"count":298,"type":21},[125],"Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.\n\nOne leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.\n\nThis study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.\n\nEarlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.",[586,587],"Recurrent Pregnancy Loss","Recurrent Miscarriages",[589,590,591,592,593,594],"T helper cells","Immunological causes of miscarriage","miscarriage","pregnancy loss","granulocyte-colony stimulating factor","G-CSF","2026-07-20",{"date":597,"type":39},"2026-07-24",{"date":599,"type":39},"2026-07-10",{"date":601,"type":21},"2027-10-10",{"name":603,"class":46},"Fakih IVF Fertility Center",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":612,"targetDuration":614,"studyType":22,"phases":4,"briefSummary":615,"conditions":616,"keywords":621,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":635},"100327946","icareme-global-registry-multinational-real-world-evidence-in-cardiorenal-and-metabolic-diseases-100327946","NCT03549754","iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases","Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and\u002For Chronic Kidney Diseases","iCaReMe","Inclusion Criteria:\n\n1. Being 18 years or older\n2. Having type 2 diabetes, Hypertension, Heart Failure and\u002For chronic kidney disease\n3. Providing written informed consent to participate in the registry\n\nExclusion Criteria:\n\n1. Having a life-threatening co-morbidity with life expectancy below 1 year\n2. Participating in an interventional trial requiring informed consent",{"count":613,"type":21},35000,"3 Years","To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and\u002For Chronic kidney diseases",[617,618,619,620],"Type 2 Diabetes","Hypertension","Chronic Kidney Disease","Heart Failure",[622,617,623,619,624,618,625,626,620,627,628],"Registry","T2DM","CKD","HTN","Adult population","HF","Early cardiorenal complications",{"date":563,"type":39},{"date":631,"type":39},"2018-02-17",{"date":633,"type":21},"2030-12-31",{"name":287,"class":68},76,{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":218,"sex":17,"minAge":78,"maxAge":642,"enrollmentInfo":643,"targetDuration":4,"studyType":82,"phases":645,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":477},"100644864","cooking-classes-as-a-family-based-intervention-for-weight-reduction-effects-on-dietary-quality-and-weight-management-in-abu-dhabi-united-arab-emirates-100644864","NCT07675148","Cooking Classes as a Family-based Intervention for Weight Reduction: Effects on Dietary Quality and Weight Management in Abu Dhabi (United Arab Emirates)","Inclusion Criteria:\n\n* Emirati\n* Based in Abu Dhabi\n* Home cooked meals prepared by full-time home cooks who are certified in the ICCA Culinary Medicine course (post 4 weeks cooking training)\n* Certified home cooks are residing with participant during the training and intervention\n* Aged between 18 years and 60 years\n* BMI between 28-40 kg\u002Fm2\n* Participant and cooks being able to provide informed consent\n\nExclusion Criteria:\n\n* Body weight exceeding 220 kilograms at the time of recruitment\n* Undergoing treatment for serious illnesses (active cancer), planned for surgery, interventional management, and immunomodulation\n* Undergone surgery within 3 months prior to study recruitment, including bariatric surgery\n* Enrolled in other lifestyle intervention programs","60 Years",{"count":644,"type":21},250,[223],"The goal of this quasi-experimental interventional study is to learn if healthy cooking classes for home cooks can improve weight management and dietary quality among Emirati adults with overweight or obesity living in Abu Dhabi. The main questions it aims to answer are:\n\n* Does participation in the culinary medicine program reduce body weight over time?\n* Does the intervention improve diet quality and increase compliance with healthy home-cooked meals?\n* Does the intervention improve health measures such as waist circumference, body fat percentage, blood pressure, and heart rate?\n* What are the experiences and satisfaction levels of participating family members and trained home cooks?\n\nParticipants will:\n\n* Enroll in a 3-month family-based nutrition intervention program\n* Receive meals prepared by home cooks trained in culinary medicine through the ICCA program\n* Complete assessments before the intervention, during the intervention, and 3 months after completion\n* Undergo measurements including weight, waist circumference, body fat percentage, blood pressure, and heart rate\n* Complete questionnaires about diet quality, meal habits, and overall program experience",[648,649],"Obesity & Overweight","Culinary Medicine","2026-07-17",{"date":595,"type":39},{"date":653,"type":39},"2025-10-08",{"date":655,"type":21},"2026-10-31",{"name":476,"class":46},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":330,"minAge":78,"maxAge":665,"enrollmentInfo":666,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":668,"conditions":669,"keywords":672,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":477},"100645392","an-investigation-of-the-effect-of-vitamin-d-level-during-frozen-embryo-transfer-fet-in-ivf-and-pregnancy-outcomes-100645392","NCT07681115","An Investigation of the Effect of Vitamin D Level During Frozen Embryo Transfer (FET) in IVF and Pregnancy Outcomes","Vitamin D Levels and Pregnancy Outcomes Following Frozen Embryo Transfer (FET) in the UAE","VitD in FET","Inclusion:\n\n* Women undergoing frozen embryo transfer (FET) at Fakih IVF.\n* Age between 18 and 40 years.\n* Body mass index (BMI) between 18 and 40 kg\u002Fm².\n* Patients who had serum vitamin D levels assessed within three months prior to FET\n* Supplementation with Vitamin D if deficient \\\u003C 30 ng\u002FmL (75 nmol\u002FL).\n\nExclusion:\n\n* Age below 18 years or above 40 years.\n* BMI below 18 kg\u002Fm² or above 40 kg\u002Fm².\n* Patients who did not have vitamin D levels measured within three months prior to FET.\n* Patients who were found to have low vitamin D levels but did not receive supplementation.\n* Patients with recurrent implantation failure (RIF).\n* Patients with known uterine factors affecting implantation (e.g., congenital uterine anomalies, intrauterine adhesions, submucosal fibroids).\n* Patients with significant medical comorbidities that may affect pregnancy outcomes.","40 Years",{"count":667,"type":21},126,"Vitamin D is best known for keeping our bones healthy, but growing research suggests it may also play a role in fertility. Many In vitro fertilization (IVF) clinics now routinely check vitamin D levels and prescribe supplements before treatment, but the science is still unclear on whether this actually improves the chances of pregnancy.\n\nOur study, based in the United Arab Emirates (UAE), aims to find out whether a woman's vitamin D level on the day of her frozen embryo transfer (FET) makes a difference to whether she becomes pregnant and delivers a baby. The UAE is an ideal setting for this research, as vitamin D deficiency is particularly common in the region. The findings could shape how fertility clinics screen and treat women seeking fertility treatment in the future.",[670,671],"Vitamin D Insufficiency","In Vitro Fertilization and Embryo Transfer",[673,674],"frozen embryo transfer cycle","Vitamin D","2026-07-13",{"date":108,"type":39},{"date":678,"type":39},"2026-06-01",{"date":680,"type":21},"2027-08",{"name":603,"class":46},""]